A multisite, longitudinal study assessing prevalence of depression in student pharmacists.

OBJECTIVE: Conduct a multisite, survey-based study assessing rates of self-reported depressive symptoms among student pharmacists enrolled in the first 3 years (P1-P3) of 4-year Doctor of Pharmacy (PharmD) curricula. METHODS: This study followed a cross-sectional observational design conducted at Washington State University, College of Pharmacy and Pharmaceutical Sciences, and the University of Arkansas for Medical Sciences, College of Pharmacy. Student pharmacists in the first 3 years of pharmacy school (P1-P3) of the PharmD curricula were invited to voluntarily complete the Center for Epidemiologic Studies Depression Scale (CES-D) to collect self-reported measures of depression. The CES-D is a validated 20-item instrument using a 4-point Likert scale. RESULTS: A total of 1795 surveys were evaluated from P1-P3 students at Washington State University, College of Pharmacy and Pharmaceutical Sciences and University of Arkansas for Medical Sciences, College of Pharmacy over a 4-year period (2019-2022). Overall, 1150 (64.1%) surveys indicated the presence of depressive symptoms on CES-D. The highest rate of reported depressive symptoms was recorded in 2021 (71.4%), notably during the coronavirus disease 2019 pandemic, whereas the lowest rate was prepandemic in 2019 (57.8%). The P1 cohort had the highest depression rate in 2020 and 2021, whereas the P2 cohort was highest in 2019 and 2022. The P3 cohort screening positive for depression increased from 52.6% to 69.3% over the 4-year period. CONCLUSION: This multisite, longitudinal study confirms that self-reported depressive symptoms in student pharmacists are significantly higher than what is reported in undergraduate students. Opportunities exist for pharmacy educators and university wellness services to better identify and serve student pharmacists experiencing depression or depressive episodes.

Implementing Mental Health First Aid Training in a Doctor of Pharmacy Program.

OBJECTIVE: In this study, we aimed to describe the implementation of Mental Health First Aid (MHFA) training as a required curricular component in a Doctor of Pharmacy (PharmD) program; and analyze the impact of MHFA training on student pharmacist's perceptions of stigma, comfort, confidence, and willingness to intervene when someone is experiencing a mental health issue. METHODS: Student pharmacists completed an all-day MHFA training as a required element of the PharmD curriculum during the spring of 2022. Pre- and post-survey was completed by students during the in-person training. Questions included items from the Opening Minds to Stigma Scale for Healthcare Providers; question, persuade, refer gatekeeper training for suicide prevention; and questions developed by the authors to assess the impact of the training on participant-reported stigma, confidence, and willingness to provide care to those potentially experiencing a mental issue. RESULTS: A total of 235 student pharmacists completed the MHFA training. A statistically significant reduction of stigma was seen for 9 of the 15 statements from Opening Minds to Stigma Scale for Healthcare Providers. Additionally, all responses related to comfort and willingness to provide care and confidence improved significantly after completing MHFA. CONCLUSION: MHFA training was implemented as a mandatory requirement for all student pharmacists in the didactic portion of a PharmD program. This training led to reduced stigma around mental illness and improved confidence, comfort, and willingness to intervene among student pharmacists.

Less is more: Deprescribing anticholinergic medications in persons with severe mental illness.

BACKGROUND: Long-term prescribing of anticholinergic medications (ACM) for antipsychotic-associated extrapyramidal symptoms (EPS) is not recommended, yet is widely prevalent. Adverse effects of ACM include memory impairment, dry mouth, constipation, blurred vision, urinary retention, and tachycardia, which can seriously impact quality of life. This quality improvement deprescription project sought to reduce chronic ACM use in patients with serious mental illness (SMI). METHODS: Education directed at psychiatrists combined with clinical pharmacy support for deprescription was used to target clinically stable patients diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder with no EPS and ACM prescriptions of ≥6 months. Scales were used to assess anticholinergic adverse effects, memory impairment, and quality of life. ACMs were tapered and discontinued over 1 to 6 months. RESULTS: More than 75% of targeted patients successfully tapered or discontinued ACM, which coincided with significant improvements in anticholinergic adverse effects, memory impairment, and quality of life. Approximately 10% of patients were restarted on ACM for re-emergent EPS. CONCLUSIONS: For most clinically stable patients with SMI without EPS, our findings suggest that gradual deprescription of chronic ACM is clinically appropriate, well tolerated, and improves quality of life. A randomized trial could provide more definitive answers.